BP-1-102

BP-1-102 is a potent, orally bioavailable small molecule inhibitor that selectively targets signal transducer and activator of transcription 3 (STAT3), specifically by binding its Src homology 2 (SH2) domain and blocking STAT3-phospho-tyrosine interactions. This inhibition prevents STAT3 phosphorylation, dimerization, and subsequent activation, leading to downregulation of STAT3-regulated genes including c-Myc, Cyclin D1, Bcl-xL, Survivin, and VEGF. BP-1-102 induces antiproliferative, pro-apoptotic, and antitumor effects in various STAT3-dependent malignancies including T-cell acute lymphoblastic leukemia (T-ALL), breast cancer, non-small cell lung cancer, and gastric adenocarcinoma. Developing institutions include the University of Central Florida; the compound is mainly studied in preclinical stages for oncology indications[1][3][5][6][7][8][10].

Other names

STAT3 Inhibitor XVIIISTAT-3 Inhibitor XVIIISTAT 3 Inhibitor XVIII